Neumora Therapeutics, Inc. (NMRA)
NASDAQ: NMRA · Real-Time Price · USD
2.100
+0.150 (7.69%)
At close: Jan 22, 2026, 4:00 PM EST
2.100
0.00 (0.01%)
After-hours: Jan 22, 2026, 7:40 PM EST
Neumora Therapeutics Employees
Neumora Therapeutics had 95 employees as of September 30, 2025. The number of employees decreased by 14 or -12.84% compared to the same quarter last year.
Employees
95
Change
-14
Growth
-12.84%
Revenue / Employee
n/a
Profits / Employee
-$2,487,337
Market Cap
356.87M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 95 | -14 | -12.84% |
| Jun 30, 2025 | 96 | -12 | -11.11% |
| Mar 31, 2025 | 103 | -17 | -14.17% |
| Dec 31, 2024 | 110 | -14 | -11.29% |
| Sep 30, 2024 | 109 | -1 | -0.91% |
| Jun 30, 2024 | 108 | -2 | -1.82% |
| Mar 31, 2024 | 120 | 12 | 11.11% |
| Dec 31, 2023 | 124 | 30 | 31.91% |
| Jun 30, 2023 | 110 | 16 | 17.02% |
| Mar 31, 2023 | 108 | 14 | 14.89% |
| Dec 31, 2022 | 94 | 6 | 6.82% |
| Mar 31, 2022 | 94 | 41 | 77.36% |
| Dec 31, 2021 | 88 | 35 | 66.04% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| AC Immune | 172 |
| Puma Biotechnology | 172 |
| X4 Pharmaceuticals | 143 |
| Foghorn Therapeutics | 112 |
| Aura Biosciences | 109 |
| Immuneering | 66 |
| Candel Therapeutics | 38 |
| Protara Therapeutics | 33 |
NMRA News
- 17 days ago - Neumora Therapeutics, Inc. (NMRA) Discusses Positive Phase 1b Results for NMRA-511 in Alzheimer's Disease Agitation Transcript - Seeking Alpha
- 17 days ago - Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming Milestones - GlobeNewsWire
- 17 days ago - Neumora Therapeutics Announces Positive Results from NMRA-511 Phase 1b Signal-Seeking Study in Alzheimer's Disease Agitation - GlobeNewsWire
- 7 weeks ago - Analyst Sees Value In Neumora's Expanding Obesity And Metabolic Pipeline - Benzinga
- 2 months ago - Neumora Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - Neumora Therapeutics to Participate in Upcoming Conferences in November - GlobeNewsWire
- 3 months ago - Neumora Therapeutics, Inc. (NMRA) Discusses NMRA-215 Preclinical Results and Portfolio Updates, Including Obesity and Alzheimer's Disease Programs Transcript - Seeking Alpha
- 3 months ago - Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-898 - GlobeNewsWire